WHANIN PHARM CO.,LTD
Financials
Valuation Metrics
WHANIN PHARM CO.,LTD's Market Cap is ₩1864B. At end of 2025 it was ₩2106B. Ranked #840 of 2,436 in KR market (top 34%), #457 of 787 on KOSPI (top 58%), #91 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 39%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 186.37B KRW | KR#840/2,436 Sec#91/234 |
| Revenue | 266.19B KRW | KR#868/2,436 Sec#43/234 |
| Net Income | 15.94B KRW | KR#727/2,436 Sec#48/234 |
| Total Assets | 481.97B KRW | KR#761/2,436 Sec#44/234 |
| Net Assets | 424.14B KRW | KR#562/2,436 Sec#34/234 |
| Employees | 653 | KR#383/2,436 Sec#33/234 |
| Value | ||
| P/E | 11.69x | KR#825/2,436 Sec#48/234 |
| P/B | 0.44x | KR#694/2,436 Sec#21/234 |
| PEG | 0.26x | KR#571/2,436 Sec#35/234 |
| P/S | 0.70x | KR#1,170/2,436 Sec#57/234 |
| EV/EBITDA | 7.59x | KR#434/2,436 Sec#14/234 |
| FCF Yield | 4.12% | KR#932/2,436 Sec#52/234 |
| Profitability | ||
| ROE | 3.76% | KR#1,143/2,436 Sec#83/234 |
| ROA | 3.31% | KR#909/2,436 Sec#80/234 |
| Op. Margin | 6.43% | KR#755/2,436 Sec#63/234 |
| Revenue Growth | 18.23% | KR#679/2,436 Sec#66/234 |
| Earnings Growth | 45.82% | KR#593/2,436 Sec#36/234 |
| Financial Health | ||
| Debt Ratio | 113.64% | KR#521/2,436 Sec#70/234 |
| Total Debt | 2.01B KRW | KR#1,890/2,436 Sec#183/234 |
| FCF | 7.69B KRW | KR#786/2,436 Sec#46/234 |
| Cash | 58.43B KRW | KR#673/2,436 Sec#36/234 |
| Current Ratio | 4.10x | KR#396/2,436 Sec#70/234 |
| Net Debt/EBITDA | -3.30x | KR#190/2,436 Sec#6/234 |
| Dividend | ||
| Div. Yield | 3.01% | KR#653/2,436 Sec#31/234 |
| Div. Growth | 0.00% | KR—/2,436 Sec—/234 |
| Performance | ||
| 1Y Return | -16.29% | KR#1,075/2,436 Sec#79/234 |
| 1M Return | 2.45% | KR#494/2,436 Sec#36/234 |
| From 52W High | -19.19% | KR#169/2,436 Sec#9/234 |
| 1Y MDD | -29.70% | KR#203/2,436 Sec#12/234 |
| Trading | ||
| Volume | 53,559 shares | KR#1,025/2,436 Sec#96/234 |
| Foreign Own. | 12.65% | KR#390/2,436 Sec#32/234 |
| Per Share | ||
| EPS | 857 KRW | KR#688/2,436 Sec#47/234 |
| BPS | 22,947 KRW | KR#459/2,436 Sec#29/234 |
Company Info
Established in 1978 and listed on the securities market in 1996, Whanin Pharmaceutical is a pharmaceutical manufacturing and sales company specializing in psychoneurotic agents. Based on 2024 IMS DATA, it holds the leading market share in the domestic psychotherapeutic drug market. With a robust drug lineup and strong network, the company boasts significant sales strengths in the psychoneurotic field and is growing with the market due to increasing prescriptions driven by the rise in mental health-related medical institutions and patient visits.